APLMW (Apollomics) EPS (Basic) : $0.00 (TTM As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Apollomics EPS (Basic)?

Apollomics's basic earnings per share (Basic EPS) for the six months ended in Jun. 2024 was $0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00.

Apollomics's EPS (Diluted) for the six months ended in Jun. 2024 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00.

Apollomics's EPS without NRI for the six months ended in Jun. 2024 was $0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was 0.00.

During the past 3 years, the average EPS without NRI Growth Rate was -533.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, Apollomics's highest 3-Year average EPS without NRI Growth Rate was -533.50% per year. The lowest was -533.50% per year. And the median was -533.50% per year.

Apollomics EPS (Basic) Historical Data

The historical data trend for Apollomics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics EPS (Basic) Chart

Apollomics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

-0.86

-1.09

-2.77

Apollomics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EPS (Basic)	Get a 7-Day Free Trial			-0.04	-2.74	-2.55	-	-

Apollomics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Apollomics's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-172.601	-	0)	/	86.7958
	=	-1.99

Apollomics's Basic EPS for the quarter that ended in Jun. 2024 is calculated as

Basic EPS (Q: Jun. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-35.206	-	0)	/	89.4808
	=	-0.39

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00

Apollomics (NAS:APLMW) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Apollomics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Apollomics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLMW) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

APLM:USA

Address

989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404

Website

https://www.apollomicsinc.com

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.